This website contains promotional content and is intended for Healthcare Professionals based in the United Kingdom only. Some content is only relevant to HCPs practising in Great Britain (England, Scotland, Wales). This website is optimised for desktop use, and some features may perform differently on mobile devices.

Adverse event reporting can be found at the bottom of the page.

Campus
  1. Article
  2. Source: Campus Sanofi
  3. 23 Oct 2023

Praluent® (alirocumab) mechanism of action

Author: Sanofi

Editorial Team

       
Praluent logo

Praluent® is a fully human monoclonal antibody1 that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9) from binding to LDL-Rs, increasing the number of LDL-Rs available to remove LDL-C from the circulation.1,2

Without PCSK9 inhibition, PCSK9 decreases the number of available LDL-Rs on liver cells, resulting in higher LDL-C levels in the bloodstream.1

PCSK9 inhibition with Praluent® increases the number of available LDL-Rs, resulting in lower LDL-C levels in the bloodstream.1

Figure © Sanofi.

Watch the video below to learn more about the mechanism of action for Praluent®

Praluent®

Find more information on Indication, Administration and Mechanism of Action and watch videos about Praluent®.

Patient Website

Find resources and support for your patients on Praluent®. Find useful links about how patients can manage their cholesterol.

Get in touch with the Dyslipidaemia Team
MAT-XU-2201545 (v5.0) Date of Preparation: October 2023
References

LDL-C=low-density lipoprotein cholesterol; LDL-R=low-density lipoprotein receptor; PCSK9i=proprotein convertase subtilisin/kexin type 9 inhibitor.

  1. Praluent Summary of Product Characteristics. Available at https://www.medicines.org.uk/emc/product/8093/smpc. Accessed October 2023.
  2. Poirier S and Mayer G. Drug Des Devel Ther 2013;7:1135–1148.

MAT-XU-2204608 (v3.0) Date of Preparation: October 2023